

## Removal of temporary benefit from the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the shortage of Nestle Materna Tablet (NPN 80082297), **Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)**, manufactured by Jamieson Laboratories, was added as a temporary benefit for the *HSDBS*.

Alberta Blue Cross® has confirmed that the shortage for Nestle Materna Tablet (NPN 80082297) has been resolved.

**Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)** will no longer be considered a temporary benefit for the *HSDBS* after **April 17, 2025**. The above grouping was removed from the Critical Supply Product List **March 17, 2025**.

### Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Efudex 5% Topical Cream (DIN 00330582), manufactured by Bausch Health, **Tolak 4% Topical Cream (DIN 02485346)**, manufactured by Hill Dermaceuticals Inc, will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **March 21, 2025**.

As of March 21, 2025, all claims for Tolak 4% Topical Cream (DIN 02485346) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/provider/type/pharmacy/home.php](http://ab.bluecross.ca/provider/type/pharmacy/home.php).

### Product supply shortages addressed for *ADBL*

Alberta Blue Cross® has confirmed that the shortage for Sandoz Alfacalcidol 1 mcg Capsule (DIN 02533324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the Least Cost Alternative (LCA) Price Policy will be reapplied to the following grouping effective **April 24, 2025**. The following grouping was removed from the Critical Supply Product List **March 25, 2025**.

#### ALFACALCIDOL

##### 1 MCG CAPSULE

00002533324	SANDOZ ALFACALCIDOL	SDZ	\$ 1.2911
00000474525	ONE-ALPHA	CAG	\$ 1.5854

continued next page

# PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross® has confirmed that the shortage for Teva-Bupropion XL 300 mg Extended-Release Tablet (DIN 02439662) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **April 25, 2025**. The following grouping was removed from the Critical Supply Product List **March 26, 2025**.

## BUPROPION HCL

### 300 MG EXTENDED-RELEASE TABLET

00002475812	TARO-BUPROPION XL	SPG	\$ 0.5853
00002439662	TEVA-BUPROPION XL	TEV	\$ 0.5853
00002275104	WELLBUTRIN XL	VCL	\$ 1.1769

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

